John Thomas Sells 3,334 Shares of Genelux Co. (NASDAQ:GNLX) Stock

Genelux Co. (NASDAQ:GNLX) Director John Thomas sold 3,334 shares of the firm’s stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $24.99, for a total transaction of $83,316.66. Following the sale, the director now owns 475,793 shares of the company’s stock, valued at approximately $11,890,067.07. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

John Thomas also recently made the following trade(s):

• On Friday, September 15th, John Thomas sold 3,333 shares of Genelux stock. The stock was sold at an average price of $21.90, for a total transaction of $72,992.70.

Genelux Trading Up 12.3 %

GNLX opened at $25.38 on Tuesday. The firm has a 50-day moving average price of $24.55 and a 200-day moving average price of $26.73. Genelux Co. has a twelve month low of $5.35 and a twelve month high of $40.98.

Genelux (NASDAQ:GNLX) last posted its earnings results on Monday, August 14th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.09). Equities research analysts anticipate that Genelux Co. will post -0.94 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Maxim Group assumed coverage on Genelux in a research report on Tuesday, September 12th. They issued a “buy” rating and a $40.00 target price for the company.

Hedge Funds Weigh In On Genelux

Hedge funds have recently made changes to their positions in the stock. California State Teachers Retirement System purchased a new position in shares of Genelux in the second quarter valued at $30,000. Tower Research Capital LLC TRC purchased a new position in Genelux during the first quarter valued at approximately $32,000. American International Group Inc. purchased a new position in Genelux during the second quarter valued at approximately $44,000. JPMorgan Chase & Co. grew its stake in Genelux by 2,105.0% during the second quarter. JPMorgan Chase & Co. now owns 2,205 shares of the company’s stock valued at $72,000 after acquiring an additional 2,105 shares in the last quarter. Finally, Global Retirement Partners LLC purchased a new position in Genelux during the second quarter valued at approximately $82,000. 10.77% of the stock is currently owned by hedge funds and other institutional investors.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer.